Placebo effect in the treatment of non-small cell lung cancer:a meta-analysis

作     者：Siyuan Ren Mengyao Ma Chuan He Yuhui Deng Xiaoyun Chen Yonglin Liu Yangyang Jin Yansong Liu Lei Cai Lin He Siyuan Ren;Mengyao Ma;Chuan He;Yuhui Deng;Xiaoyun Chen;Yonglin Liu;Yangyang Jin;Yansong Liu;Lei Cai;Lin He

作者机构：Bio-X InstitutesKey Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders(Ministry of Education)Collaborative Innovation Center for Genetics and DevelopmentShanghai Mental Health CenterShanghai Jiao Tong University Shanghai Center for Women and Children’s Health Department of RheumatologyLonghua HospitalShanghai University of Traditional Chinese MedicineShanghai Sanya Maternal and Child Health HospitalSanyaHainan Province Faculty of Medical Laboratory ScienceRuijin HospitalShanghai Jiao Tong University School of MedicineShanghai Department of Clinical PsychologySuzhou Guangji HospitalThe Affiliated Guangji Hospital of Soochow UniversitySuzhouJiangsu ProvinceChina 

出 版 物：《Journal of Bio-X Research》 (生物组学研究杂志（英文）)

年 卷 期：2022年第5卷第3期

页      面：132-140页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Natural Science Foundation of Shanghai(No.19ZR1427700) Ministry of Science and Technology of China(No.2017YFC1001302) Shanghai Key Laboratory of Psychotic Disorders(13dz2260500)in Shanghai Mental Health Center,China(No.19-K02) 

主　　题：lung cancer meta-analysis NSCLC palliative care placebo effect 

摘      要：Objective:The majority of non-small cell lung cancer(NSCLC)cases remain undiagnosed until advanced stages of the *** studies have highlighted the utility of palliative care as an effective treatment option,which relieves patients’suffering by activating placebo effect in the *** evaluate the clinical significance of palliative care,data from NSCLC drug-randomized controlled trials(RCTs)were collected and the effects of placebo treatment ***:PubMed(MEDLINE),Scopus,Web of Science,and China National Knowledge Infrastructure databases were searched from January 1,1978 to September 1,***-controlled phase II/III pharmaceutical RCTs enrolling patients with solely stage III/IV NSCLC were *** quality of included studies was assessed using the Jadad ***-arm and two-arm meta-analyses of the therapeutic and adverse effects of placebo,that is,the primary and secondary outcome measures,were subsequently performed using either Bayesian or conventional ***:Five RCTs including 2245 drug-treated and 1510 placebo-treated patients at NSCLC stage III or IV were included for the *** risk of bias was observed for all five included studies using the Cochrane *** placebo treatment,controlled disease rate of 24.1%(95%credible interval[CrI],-0.126-0.609)and dropout rate of 2.1%(95%CrI,0.007-0.039)were calculated,with a dose reduction rate of 3.0%(95%CrI,0.017-0.045).Compared with active drug treatment,the placebo treatment group had a risk ratio of 0.81(95%confidence interval,0.68-0.97)and 0.85(95%confidence interval,0.76-0.96)for the achievement of progression-free survival and overall survival,***:In NSCLC drug RCTs,placebo treatment is indicated to generally induce low toxicity in patients by dropout and dose reduction rates and adverse events,although the therapeutic responses could not be precisely *** results suggest that under specific circumstances,palliative care